First Berlin keeps Jaguar Health rating under review, price target under review

Reuters2026/08/28 12:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

First Berlin Equity Research kept its “Under Review” recommendation on Jaguar Health in an update.
Q2 2026 product revenue fell to USD 1.2 million from USD 2.9 million, reflecting the Future Pak licensing shift to cost-plus supply.
OpEx declined to USD 8.8 million from USD 11 million, narrowing the operating loss to USD 7.6 million from USD 8 million.
Notes payable dropped to USD 15.6 million at June 30 from USD 42.5 million at year-end 2025, turning equity to USD 4.9 million.
Key pressure points flagged: USD 1.5 million monthly minimum royalties restarting in October 2026, USD 6.6 million secured note maturity, USD 40 million ELOC backstop.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EQS News (Ref. ID: rc_26666) on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

First Berlin keeps Jaguar Health rating under review, price target under review

You may also like

Crypto prices